Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s share price rose 6.7% on Tuesday . The stock traded as high as C$1.63 and last traded at C$1.59. Approximately 167,300 shares traded hands during trading, an increase of 121% from the average daily volume of 75,656 shares. The stock had previously closed at C$1.49.
Cardiol Therapeutics Stock Performance
The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The stock has a 50-day moving average price of C$1.48 and a 200-day moving average price of C$1.89. The firm has a market capitalization of C$131.11 million, a PE ratio of -3.11 and a beta of 0.70.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Recommended Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
